Li Dezhi, Zhou Yu, Liu Yanhui, Lin Ye, Yu Min, Lu Xin, Huang Bowen, Sun Zhonghai, Jian Zhixiang, Hou Baohua
Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China.
Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China.
Onco Targets Ther. 2018 Mar 6;11:1259-1265. doi: 10.2147/OTT.S154168. eCollection 2018.
Liver kinase B1 (LKB1) is a key regulatory protein of cellular metabolism, proliferation, and polarity. The present study aimed to characterize the expression pattern of LKB1 in pancreatic neuroendocrine tumors (pNETs) and evaluate the relationship between LKB1 expression and prognosis in pNETs.
We retrospectively analyzed the pathologic and clinical data of 71 pNET patients who underwent curative surgical resection in Guangdong General Hospital. LKB1 mRNA and protein levels in tumor tissues and paired nontumor tissues were evaluated in 24 patients by quantitative real-time reverse-transcription polymerase chain reaction and Western blot, respectively. Immunohistochemical expression of LKB1 in tumor tissues was detected in all of the 71 patients, and the immunohistochemical expression level was re-coded in two classes (high versus low/negative) and correlated with clinicopathological parameters and survival outcomes. The association between LKB1 expression and clinicopathological characters was evaluated by chi-square test and Student's -test. Kaplan-Meier curves and log-rank test were used to analyze the survival outcomes, including overall survival (OS) and disease-free survival (DFS).
Compared to adjacent normal tissues, LKB1 mRNA level and protein expression level in tumor tissues were both increased. The immunostaining of LKB1 was mainly found within the cytoplasm. Overall, 52 of 71 (73.2%) cases were positive for LKB1 protein, which showed either a diffuse staining pattern or a partial staining pattern. Decreased LKB1 expression was correlated with older age (=0.042), increased Ki-67 index (=0.004), increased mitotic count (=0.001), and advanced histologic grade (=0.001). Moreover, patients with low/negative LKB1 expression had shorter OS and DFS than those with high expression.
Our results suggested that LKB1 expression could be a useful prognostic marker for recurrence and survival in pNET patients who had received curative resection.
肝脏激酶B1(LKB1)是细胞代谢、增殖和极性的关键调节蛋白。本研究旨在描述LKB1在胰腺神经内分泌肿瘤(pNETs)中的表达模式,并评估LKB1表达与pNETs预后之间的关系。
我们回顾性分析了在广东省人民医院接受根治性手术切除的71例pNET患者的病理和临床资料。分别通过定量实时逆转录聚合酶链反应和蛋白质免疫印迹法评估了24例患者肿瘤组织及配对的非肿瘤组织中LKB1 mRNA和蛋白水平。检测了所有71例患者肿瘤组织中LKB1的免疫组化表达,并将免疫组化表达水平重新编码为两类(高表达与低表达/阴性),并与临床病理参数和生存结果进行关联分析。采用卡方检验和t检验评估LKB1表达与临床病理特征之间的关联。采用Kaplan-Meier曲线和对数秩检验分析生存结果,包括总生存期(OS)和无病生存期(DFS)。
与相邻正常组织相比,肿瘤组织中LKB1 mRNA水平和蛋白表达水平均升高。LKB1免疫染色主要见于细胞质内。总体而言,71例患者中有52例(73.2%)LKB1蛋白呈阳性,表现为弥漫性染色或局灶性染色。LKB1表达降低与年龄较大(P=0.042)、Ki-67指数升高(P=0.004)、有丝分裂计数增加(P=0.001)及组织学分级较高(P=0.001)相关。此外,LKB1表达低/阴性的患者的OS和DFS均短于高表达患者。
我们的结果表明,LKB1表达可能是接受根治性切除的pNET患者复发和生存的有用预后标志物。